98 related articles for article (PubMed ID: 23706224)
1. Synthesis of novel chitosan-silica/CpG oligodeoxynucleotide nanohybrids with enhanced delivery efficiency.
Chen S; Zhang H; Chinnathambi S; Hanagata N
Mater Sci Eng C Mater Biol Appl; 2013 Aug; 33(6):3382-8. PubMed ID: 23706224
[TBL] [Abstract][Full Text] [Related]
2. Microfluidic generation of chitosan/CpG oligodeoxynucleotide nanoparticles with enhanced cellular uptake and immunostimulatory properties.
Chen S; Zhang H; Shi X; Wu H; Hanagata N
Lab Chip; 2014 Jun; 14(11):1842-9. PubMed ID: 24733088
[TBL] [Abstract][Full Text] [Related]
3. Recognition of CpG oligodeoxynucleotides by human Toll-like receptor 9 and subsequent cytokine induction.
Suwarti S; Yamazaki T; Svetlana C; Hanagata N
Biochem Biophys Res Commun; 2013 Jan; 430(4):1234-9. PubMed ID: 23266611
[TBL] [Abstract][Full Text] [Related]
4. Cytosine-phosphodiester-guanine oligodeoxynucleotide (CpG ODN)-capped hollow mesoporous silica particles for enzyme-triggered drug delivery.
Zhu Y; Meng W; Hanagata N
Dalton Trans; 2011 Oct; 40(39):10203-8. PubMed ID: 21901222
[TBL] [Abstract][Full Text] [Related]
5. Effect of molecular weight of polyethyleneimine on loading of CpG oligodeoxynucleotides onto flake-shell silica nanoparticles for enhanced TLR9-mediated induction of interferon-α.
Manoharan Y; Ji Q; Yamazaki T; Chinnathambi S; Chen S; Ganesan S; Hill JP; Ariga K; Hanagata N
Int J Nanomedicine; 2012; 7():3625-35. PubMed ID: 22888224
[TBL] [Abstract][Full Text] [Related]
6. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
Ren T; Wen ZK; Liu ZM; Qian C; Liang YJ; Jin ML; Cai YY; Xu L
Cancer Invest; 2008 Jun; 26(5):448-55. PubMed ID: 18568766
[TBL] [Abstract][Full Text] [Related]
7. Nuclease-resistant immunostimulatory phosphodiester CpG oligodeoxynucleotides as human Toll-like receptor 9 agonists.
Meng W; Yamazaki T; Nishida Y; Hanagata N
BMC Biotechnol; 2011 Sep; 11():88. PubMed ID: 21943407
[TBL] [Abstract][Full Text] [Related]
8. Chitosan-coated boron nitride nanospheres enhance delivery of CpG oligodeoxynucleotides and induction of cytokines.
Zhang H; Chen S; Zhi C; Yamazaki T; Hanagata N
Int J Nanomedicine; 2013; 8():1783-93. PubMed ID: 23674892
[TBL] [Abstract][Full Text] [Related]
9. Cross-talk between toll-like receptors 5 and 9 on activation of human immune responses.
Merlo A; Calcaterra C; Mènard S; Balsari A
J Leukoc Biol; 2007 Sep; 82(3):509-18. PubMed ID: 17586660
[TBL] [Abstract][Full Text] [Related]
10. BN nanospheres functionalized with mesoporous silica for enhancing CpG oligodeoxynucleotide-mediated cancer immunotherapy.
Zhang H; Cheng T; Lai L; Deng S; Yu R; Qiu L; Zhou J; Lu G; Zhi C; Chen J
Nanoscale; 2018 Aug; 10(30):14516-14524. PubMed ID: 30024003
[TBL] [Abstract][Full Text] [Related]
11. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
[TBL] [Abstract][Full Text] [Related]
12. CpG oligodeoxynucleotide and double-stranded RNA synergize to enhance nitric oxide production and mRNA expression of inducible nitric oxide synthase, pro-inflammatory cytokines and chemokines in chicken monocytes.
He H; MacKinnon KM; Genovese KJ; Kogut MH
Innate Immun; 2011 Apr; 17(2):137-44. PubMed ID: 20083501
[TBL] [Abstract][Full Text] [Related]
13. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release.
Hong Z; Jiang Z; Liangxi W; Guofu D; Ping L; Yongling L; Wendong P; Minghai W
Int Immunopharmacol; 2004 Feb; 4(2):223-34. PubMed ID: 14996414
[TBL] [Abstract][Full Text] [Related]
14. Effects of CpG-B ODN on the protein expression profile of swine PBMC.
Nagarajan G; Kuo CC; Liang CM; Chen CM; Liang SM
Vet Res; 2007; 38(6):795-808. PubMed ID: 17727805
[TBL] [Abstract][Full Text] [Related]
15. NK cells stimulated with IL-15 or CpG ODN enhance rituximab-dependent cellular cytotoxicity against B-cell lymphoma.
Moga E; Alvarez E; Cantó E; Vidal S; Rodríguez-Sánchez JL; Sierra J; Briones J
Exp Hematol; 2008 Jan; 36(1):69-77. PubMed ID: 17959301
[TBL] [Abstract][Full Text] [Related]
16. Synergy of CpG oligodeoxynucleotide and double-stranded RNA (poly I:C) on nitric oxide induction in chicken peripheral blood monocytes.
He H; Genovese KJ; Nisbet DJ; Kogut MH
Mol Immunol; 2007 May; 44(12):3234-42. PubMed ID: 17339052
[TBL] [Abstract][Full Text] [Related]
17. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
Li N; Fan XG; Tang SE; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
[TBL] [Abstract][Full Text] [Related]
18. The newly identified CpG-N ODN208 protects mice from challenge with CpG-S ODN by decreasing TNF-alpha release.
Wang L; Jiang W; Ding G; Cao H; Lu Y; Luo P; Zhou H; Zheng J
Int Immunopharmacol; 2007 May; 7(5):646-55. PubMed ID: 17386412
[TBL] [Abstract][Full Text] [Related]
19. A facilely controlled length, cytotoxicity, length-dependent and cell type-dependent cellular uptake of silica nanotubes and their applications in the delivery of immunostimulatory CpG oligodeoxynucleotides.
Chen S; Zhang Q; Jia L; Du X; Hanagata N
J Mater Chem B; 2015 Sep; 3(36):7246-7254. PubMed ID: 32262832
[TBL] [Abstract][Full Text] [Related]
20. Alpha 2-macroglobulin binds CpG oligodeoxynucleotides and enhances their immunostimulatory properties by a receptor-dependent mechanism.
Anderson RB; Cianciolo GJ; Kennedy MN; Pizzo SV
J Leukoc Biol; 2008 Feb; 83(2):381-92. PubMed ID: 17967834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
